This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Spero (SPRO) Application for UTI Drug Gets Priority Review
by Zacks Equity Research
Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
Best Growth Stocks to Buy for January 4th
by Zacks Equity Research
ABG, PFE, and APO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 4, 2022
Company News for Jan 3, 2022
by Zacks Equity Research
Companies In The News Are: PFE, CTRA, AMD, XLNX, NVAX.
Novavax (NVAX) Further Delays FDA Filing for COVID-19 Vaccine
by Zacks Equity Research
Novavax's (NVAX) filing with the FDA seeking approval for emergency use authorization of its COVID-19 vaccine, NVX-CoV2373, gets further postponed to January 2022.
Here's Why Pfizer (PFE) Appears Strongly Placed for 2022
by Kinjel Shah
While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver
J&J (JNJ) COVID Booster Jab Shows Effectiveness Against Omicron
by Zacks Equity Research
Johnson & Johnson's (JNJ) COVID booster vaccine demonstrates 85% effectiveness against COVID-related hospitalization in South Africa, with Omicron becoming the dominant variant.
Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group
by Zacks Equity Research
Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $57.58, moving -0.74% from the previous trading session.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
5 Sector ETFs That Crushed the Market in December
by Sweta Killa
With just a few trading sessions left to end December, the S&P 500 index has gained 4.8%. A few sector ETFs have outperformed.
Novavax (NVAX) COVID Jab Gets Nod for Emergency Use in India
by Zacks Equity Research
Novavax (NVAX) secures approval in India for emergency use of its COVID-19 vaccine.
Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?
by Zacks Equity Research
Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.
Holiday Sales Boom: Retail ETFs to Buy At a Bargain
by Sweta Killa
Retail sales surged the most in nearly two decades this holiday season powered by soaring ecommerce sales as well as a rush to stores amid supply chain concerns, rising inflation and the raging new COVID-19 variant.
Stock Market News for Dec 27, 2021
by Zacks Equity Research
U.S. stocks closed higher for the third consecutive day on Thursday, with the S&P 500 hitting a record high ahead of a long Christmas holiday weekend as investors shed fears and felt more optimistic that the Omicron variant of the coronavirus won¿¿¿t affect global economy growth.
Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use
by Zacks Equity Research
Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.
Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs
by Kinjel Shah
FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).
Pfizer ETFs to Rise on FDA's EUA for COVID-19 Oral Antiviral Pill
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the receipt of EUA for the antiviral COVID-19 pill.
Santa Arrives! High Beta & Momentum ETFs to Tap the Rally
by Sweta Killa
With the Santa Claus rally, high-beta and high-momentum ETFs are expected to outperform in the seven-day period and are intriguing choices for a short spell.
Moderna (MRNA) Down as Pfizer Paxlovid EUA May Fuel Competition
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine may face stiffer competition following the FDA's emergency approval of an oral COVID-19 pill, Pfizer's Paxlovid, which may result in lower sales.
Pfizer (PFE) Gets FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill Paxlovid is the first oral antiviral medicine, which can be prescribed as an at-home treatment for mild-to-moderate COVID-19.
Stock Market News for Dec 23, 2021
by Zacks Equity Research
Wall Street closed higher on Wednesday completing back-to-back rallies after three-days of Omicron-led decline.
Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Pfizer (PFE) Stock Moves 1.02%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $59.55, marking a +1.02% move from the previous day.
Markets Stay Up on Omicron News; Home Sales in Focus
by Mark Vickery
Today and yesterday, we've begun to see an influx of reports about Omicron blowing through populations rapidly but rather benignly.